- Stemline Therapeutics, Inc. stock price today and history
Stemline Therapeutics, Inc. (STML) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Stemline Therapeutics, Inc. stock price
Stemline Therapeutics, Inc. latest news:
Stemline Therapeutics shares jump 4% premarket after positive trial of leukemia treatment
Shares of biotech Stemline Therapeutics Inc. jumped 4% premarket Wednesday, after the company said a trial of a treatment for acute myeloid leukemia met its main goal. Stemline said data from the trial of its SL-401 therapy in blastic plasmacytoid dendritic cell neoplasm (BPDCN), a highly aggressive, lethal malignancy of unmet medical need, with no approved therapies, showed it met its primary endpoint. The trial involved 45 patients and data was presented at this week's American Society of Hematology annual meeting. "The remarkable data presented at ASH from our pivotal trial with SL-401 in BPDCN sets the stage for our upcoming BLA submission and a successful 2018," Stemline Chief Executive Ivan Bergstein said in a statement. Shares have gained 43% in 2017, while the S&P 500 has gained 19%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Stemline Therapeutics reports Q3 loss per share $0.68
Stemline Therapeutics Inc(STML). * Stemline Therapeutics(STML) reports third quarter 2017 financial results.
Sterling Construction Company IncSTRL
Steven Madden, Ltd.SHOO
Stewardship Financial CorpSSFN
Stock Building Supply Holdings, Inc.STCK
Stock Yards Bancorp, Inc.SYBT
StoneCastle Financial CorpBANX